Thomas Lingelbach

Thomas Lingelbach joined Intercell as Chief Operating Officer in 2006 and has been appointed as a new member of Intercell's Management Board in 2007.

He has held a variety of positions of increasing international responsibility in his twenty years in the pharma and vaccine industry; from 2001 until Chiron's acquisition by Novartis early in 2006, he served as Vice President of Industrial Operations in Chiron Vaccines’ Executive Committee and Managing Director for Chiron-Behring in Germany.

Before joining Intercell, he was significantly involved in Novartis' integration activities acting as General Manager and Managing Director for its German operations. His responsibilities include Product Development, Manufacturing, Quality & Regulatory Compliance and Marketing, Sales and Supply.

Thomas Lingelbach is Managing Director of Intercell Biomedical Ltd. and President and CEO of Intercell USA, Inc. He holds a Master's degree in Engineering and complemented his education with a Business Administration program.